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Malignant Hyperthermia
Daniel Talbot, RN BSN CCRN
Otterbein University, Westerville, Ohio
Introduction
Malignant hyperthermia,
according to the Orphanet
Journal of Rare Diseases, is
“pharmacogenetic disorder of
skeletal muscle that presents as a
hypermetabolic response to
potent volatile anesthetic gases”
(Rosenberg, Pollock, Shiemann,
Bulger, and Stowell, 2015, p. 1).
Its incidence in anesthetics is 1
in 10,000 to 1 in 250,000, and
the prevalence is increased in an
individual with certain genetic
abnormalities that may be as
common as one in every 400
people. It is caused by the
uncontrolled rise in myoplasmic
calcium, leading to a cascade of
muscle activation. The
symptoms of malignant
hyperthermia include
hyperthermia, tachypnea,
tachycardia, increased oxygen
consumption and carbon dioxide
production, acidosis,
hyperkalemia, muscle rigidity,
and rhabdomyolysis. It is a
condition that is likely to be fatal
if untreated (Rosenberg et al.,
2015). The specific treatment
for this condition is the
antagonist dantrolene sodium,
which must be readily available
whenever general anesthesia is
utilized (Eagle Pharmaceuticals,
2016).
As the chief purpose of the
certified registered nurse
anesthetist is to administer safe
and effective anesthesia to
patients of many backgrounds
and circumstances, intimate
knowledge and preparation for
malignant hyperthermia is of
paramount import to me and my
chosen career. I chose this topic
because it is one that I had only
passing knowledge of. Detailed
investigation into the etiology
and pathophysiology of the
condition, the early warning
signs and different
manifestations, and identification
of effective steps for treatment
and crisis management are all
important areas of discovery for
the CRNA. It is for this reason
that malignant hyperthermia is a
warranted and prudent topic of
study.

Signs and Symptoms
Early
Masseter Spasm
Generalized Muscular Rigidity
Tachycardia
Hypercapnia
Hypoxia
Combined Metabolic-Respiratory
Acidosis
Late
Hyperthermia
Rhabdomyolysis
Acute Renal Failure
Cardiac Arrhythmia
Hypotension
Circulatory Failure
(Schneiderbanger, Johannsen, Roewer,
& Schuster, 2014)
Though hyperthermia is in the name of
the condition, it is itself often a late
sign and is reflective of the metabolic
breakdown in the patient. Thus, it is
necessary to watch for all early signs,
though occasionally the increase in
temperature is the only outward sign.
(Schuster, Johannsen, Schneiderbanger,
& Roewer, 2013).

Underlying
Pathophysiology
Malignant hyperthermia is a
pharmacogenetic disorder which results in
a hypermetabolic state. The signs and
symptoms of MH are related to an
uncontrolled release of intracellular
calcium from skeletal muscle sarcoplasmic
reticulum. It occurs as a result of a
reaction to inhaled anesthetics or the
skeletal muscle relaxant succinylcholine in
susceptible people. It is an autosomal
dominant inherited disorder, and thus a
child of a susceptible patient has a 50%
chance of inheriting a defective gene
(Mitchell-Brown, 2012). A susceptible
individual will possess a defective or
disordered calcium channel in their
sarcoplasmic reticulum termed the
ryanodine receptor (RyR1). As many as
70% of families susceptible to MH possess
one of the 34 causal mutations for the
disorder (Rosenberg, Pollock, Schiemann,
Bulger, & Stowell, 2015). The increase in
intracellular calcium results in the muscles
metabolizing, contracting, and causing a
subsequent increase in oxygen
consumption and carbon dioxide
production, as well as ATP hydrolysis and
heat production.
During the excitation-contraction
coupling, acetylcholine causes an action
potential at the neuromuscular endplate.
This action potential is then propagated to
the transverse tubule, causing a
displacement of the charge at the
dihydropyridine receptor. This voltagegated receptor directly transmits to the
RyR1, opening the channel and leading to
the large influx of calcium into the cytosol.
This calcium presence causes the muscle
contraction by initiation of cross-linking
myofilaments. Normally, active reuptake
of the calcium would stop the muscle
contraction, however in an MH crisis, the
defective receptor stays open. This
constant activation of aerobic and
anaerobic metabolism leads to the increase
in oxygen consumption, hypoxia, lactate
acidosis, excessive CO2 production, and
increase in bodily temperature.
Eventually, as the cellular ATP is depleted,
the membrane integrity of the muscle cells
will break down and rhabdomyolysis will
occur from the potassium, creatine
phosphokinase, and myoglobin that are
released from the cells (Schneiderbanger,
et al., 2014).

(Schneiderbanger, et al., 2014)

Significance of Pathophysiology
Malignant hyperthermia is rare and life threatening. Early recognition, diagnosis, and
treatment with dantrolene sodium have reduced the mortality rate from MH from 80% in
the 1970s to less than 5% by 2006 (Rosenberg, et al., 2015). Many clinicians may be
unprepared for a crisis, failing to acknowledge the early signs and symptoms of the
condition until it has progressed to a dangerous level. The prognosis for a patient
suffering from a MH crisis is based on how soon MH is suspected and how quickly the
appropriate treatments are performed.
•
•
•
•
•
•
•
•

Stop the trigger agent immediately
Continue anesthesia using intravenous opioids, sedatives, or nondepolarizing
muscle relaxants if necessary
Initiate Malignant Hyperthermia Response Team
Give Dantrolene 2.5mg/kg and repeat as needed every 5 minutes until cardiac
and respiratory stabilization
Removal of the vaporizer used for volatile anesthesia administration
Hyperventilation of the patient with 100% oxygen at maximum fresh gas flow
Increasing minute volume by approximately 2-3 times, aiming for end-tidal pCO2
within normal limits
Cool patient if core temperature greater than 39˚C using cold infusions or ice
packs in the axilla or groin
(Schneiderbanger, et al., 2014), (Eagle Pharmaceuticals, 2016).

Following these steps, it may be necessary to utilize volume resuscitation,
vasopressor administration for hemodynamic instability, blood gas analysis and lab
draws, treatment of acidosis, or administration of beta blockers or amiodarone for
arrhythmia.
Identification for at-risk patients is of key import, as one can suspect a reaction
from the start. The definitive standard for diagnosis is an in vitro contracture test
(IVCT), which is based on contracture of muscle fibers in the presence of halothane or
caffeine. This method has more than
97% specificity, though it is expensive,
only available at certain testing
centers, requires a surgical procedure
to obtain the tissue sample, and has
the possibility of yielding a false
positive or negative result.
Alternatively, susceptibility can also be
tested by DNA analysis. 50-70% of
susceptibility is linked to the defective
RyR1 with over 400 variants noted to
have MH association (Rosenberg, et al.,
2015).

Known Drug
Triggers:
Inhalation Anesthetic Agents:
•
Desflurane
•
Enflurane
•
Halothane
•
Isoflurane
•
Methoxyflurane
•
Sevoflurane
•
Ether
Depolarizing Muscle Relaxant:
•
Succinylcholine
(Schuster, et al., 2014)

Implications for Nursing Care
Given the gravity of the condition and its potential for devastating consequences, a
prudent nurse or CRNA will do well to be mindful of the drugs that can cause the crisis,
the early warning signs of a reaction, and the correct steps for treatment to ensure rapid,
effective intervention. Knowing a patient’s preoperative condition, be it through familial
history or through genetic testing, can allow a practitioner to be ready for all eventualities
during a case. To improve skills, identification, and proper reactions, literature suggests
the validity of simulation and team-based practice drills. These exercises, ideally
performed at least once per year, will keep staff updated, alert, and improve collaboration.
This education is potentially life-saving. Knowing protocols, guidelines, and how to
prepare and administer dantrolene sodium are of chief importance. Nurses are also
responsible for the education of their patients. When a patient who has had MH is to be
discharged, it is imperative to teach these individuals so that their children and siblings
realize their susceptibility, as well. This knowledge could potentially save a life in the
future (Theofanis, 2015). The American Association of Nurse Anesthetists, in their crisis,
preparedness, and treatment publication (2015), suggest all anesthesia professionals
delivering MH trigger agents have all requisite drugs, supplies, and emergency equipment
readily available. This includes stocking dantrolene sodium at all ambulatory surgical
centers and offices. Effective drills for the management of MH include the following:
•
Visual aids to illustrate dantrolene preparation and administration
•
Cognitive aids and written Instructions for management/treatment steps
•
“Reader” who is responsible to read the cognitive aids aloud, which is shown to help
with all actions being performed properly
•
Checklists, shown to result in six-fold reduction in failure to perform all critical
steps
•
Rotation of personnel responsibilities for MH cart helps to familiarize all team
members with cart contents and identify out of date or out of stock items
•
Use of emergency whiteboard for designating team assignments illustrates clear
roles
•
MH Hotline Contact Information: 1-800-644-9737 (1-800-MH-HYPER)
(Cain, Reiss, Gettrust, & Novalija, 2014).

Conclusion
Malignant hyperthermia is a rare,
life-threatening, autosomal-dominant
inherited disorder that may lead to a
metabolic crisis of skeletal muscle in
susceptible individuals following
exposure to triggering agents, such as
volatile anesthetics or depolarizing
muscle relaxants. Functionally altered
calcium release channels cause influx of
intracellular calcium from the
sarcoplasmic reticulum, which may lead
rapidly to a fatal hypermetabolic state
known as MH crisis. Because of the
variable clinical presentation of MH,
ranging from only mild or moderate
symptoms to complete MH crises,
patient survival depends on early recognition of symptoms and prompt action
with appropriate treatments. In clinics
that use known MH-triggering agents for
induction and maintenance of general
anesthesia, dantrolene must be available
for immediate treatment, and those
practitioners present must be trained in
its use so that in the time of need the
reaction is swift and effective
(Schneiderbanger, et al., 2014).
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